Drug Trial Radar · NCT02828020
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,672
Actual
Start
Jul 22, 2016
Primary completion
Dec 13, 2017
Study completion Dec 14, 2017
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
Conditions
- Migraine, With or Without Aura
Interventions
UbrogepantDrug
50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching UbrogepantDrug
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Pain Freedom at 2 Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose
- Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose
Locations
90 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Advantage, Inc./Desert Clinical Research, LLC.
Mesa, Arizona
Xenoscience, Inc.
Phoenix, Arizona
Clinical Research Advantage, Inc./Orange Grove Family Practice
Tucson, Arizona
Principals Research Group, Inc.
Hot Springs, Arkansas
KLR Business Group, Inc. dba Arkansas Clinical Research
Little Rock, Arkansas
The Research Center of Southern California, LLC
Carlsbad, California
Med Center
Carmichael, California
T. Joseph Raoof MD, Inc./Encino Research Center
Encino, California
Neurology Center of North Orange County
Fullerton, California
Behavioral Research Specialists, LLC
Glendale, California
Prime Care Clinical Research
Laguna Hills, California
Collaborative Neuroscience Network, LLC.
Long Beach, California
Synergy San Diego
National City, California
Newport Beach Clinical Research Associates, Inc.
Newport Beach, California
North County Clinical Research
Oceanside, California
Medical Center for Clinical Research
San Diego, California
CA Medical Clinic for Headache
Santa Monica, California
Southern California Research LLC
Simi Valley, California
Encompass Clinical Research
Spring Valley, California
Alpine Clinical Research Center, Inc.
Boulder, Colorado
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Delta Waves, Inc
Colorado Springs, Colorado
Denver Neurological Research
Denver, Colorado
Associated Neurologists, P.C.
Danbury, Connecticut
Associated Neurolgists of Southern Connecticut, PC
Fairfield, Connecticut
Sarkis Clinical Trials
Gainesville, Florida
CPI MD Clinical
Hallandale, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Palm Beach Neurological Center/Advanced Research Consultants, Inc.
Palm Beach Gardens, Florida
Meridien Research
Spring Hill, Florida
University of South Florida
Tampa, Florida
Meridien Research
Tampa, Florida
Neurology Research Institute
West Palm Beach, Florida
Midtown Neurology
Atlanta, Georgia
Columbus Regional Research Institute
Columbus, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
Great Lakes Clinical Trials
Chicago, Illinois
Deaconess Clinic, Medical Office Building 1 Research Institute
Newburgh, Indiana
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.